RGMA and IL21R show association with experimental inflammation and multiple sclerosis

Genes and Immunity

Volumn 11, Issue 4, 2010, Pages 279-293

  Nohra, R ^a   Beyeen, A D ^a   Guo, J P ^a   Khademi, M ^a   Sundqvist, E ^a   Hedreul, M T ^a   Sellebjerg, F ^b   Smestad, C ^c   Oturai, A B ^b   Harbo, H F ^c,d   Wallstrom E ^a   Hillert, J ^a   Alfredsson, L ^a   Kockum, I ^a   Jagodic, M ^a   Lorentzen, J ^a   Olsson, T ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Rigshospitalet   (Denmark)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Autoimmunity; Experimental autoimmune encephalomyelitis; IL21R; Multiple sclerosis; RGMA

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GENE PRODUCT; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 6; MEMBRANE PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PRISTANE; PROTEIN EAE30; PROTEIN EAE31; PROTEIN RGMA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADVANCED INTERCROSS LINE; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CASE CONTROL STUDY; CEREBROSPINAL FLUID; CHROMOSOME 1; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXPERIMENTAL MODEL; FEMALE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC LINKAGE; HAPLOTYPE; INFLAMMATORY DISEASE; MALE; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; RAT; SEX RATIO; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

RATTUS;

EID: 77953123001     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2009.111     Document Type: Article

References (63)

1. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol 2008; 7: 268-277.
2. Chao MJ, Barnardo MC, Lincoln MR, Ramagopalan SV, Herrera BM, Dyment DA et al. HLA class I alleles tag HLA-DRB1*1501 haplotypes for differential risk in multiple sclerosis susceptibility. Proc Natl Acad Sci USA 2008; 105: 13069-13074.
3. Lincoln MR, Montpetit A, Cader MZ, Saarela J, Dyment DA, Tiislar M et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet 2005; 37: 1108-1112.
4. Olerup O, Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens 1991; 38: 1-15.
5. Olsson T, Hillert J. The genetics of multiple sclerosis and its experimental models. Curr Opin Neurol 2008; 21: 255-260.
6. Sawcer S. The complex genetics of multiple sclerosis: pitfalls and prospects. Brain 2008; 131(Part 12): 3118-3131.
7. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851-862.
8. Lundmark F, Duvefelt K, Iacobaeus E, Kockum I, Wallstrom E, Khademi M et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007; 39: 1108-1113.
9. Weber F, Fontaine B, Cournu-Rebeix I, Kroner A, Knop M, Lutz S et al. IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun 2008; 9: 259-263.
10. International Multiple Sclerosis Genetics Consortium (IMSGC). Refining genetic associations in multiple sclerosis. Lancet Neurol 2008; 7: 567-569.
11. Australia New Zealand Multiple Sclerosis Genetics Consortium (ANZgene). Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet 2009; 41: 824-828.
12. International Multiple Sclerosis Genetics Consortium (IMSGC). The expanding genetic overlap between multiple sclerosis and type I diabetes. Genes Immun 2009; 10: 11-14.
13. Rubio JP, Stankovich J, Field J, Tubridy N, Marriott M, Chapman C et al. Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians. Genes Immun 2008; 9: 624-630.
14. De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, Aggarwal NT et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009; 41: 776-782.
15. Vyse TJ, Todd JA. Genetic analysis of autoimmune disease. Cell 1996; 85: 311-318.
16. Jagodic M, Kornek B, Weissert R, Lassmann H, Olsson T, Dahlman I. Congenic mapping confirms a locus on rat chromosome 10 conferring strong protection against myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. Immunogenetics 2001; 53: 410-415.
17. Aitman TJ, Critser JK, Cuppen E, Dominiczak A, Fernandez-Suarez XM, Flint J et al. Progress and prospects in rat genetics: a community view. Nat Genet 2008; 40: 516-522.
18. Steinman L. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 1999; 24: 511-514.
19. Weissert R, Wallstrom E, Storch MK, Stefferl A, Lorentzen J, Lassmann H et al. MHC haplotype-dependent regulation of MOG-induced EAE in rats. J Clin Invest 1998; 102: 1265-1273.
20. Issazadeh S, Lorentzen JC, Mustafa MI, Hojeberg B, Mussener A, Olsson T. Cytokines in relapsing experimental autoimmune encephalomyelitis in DA rats: persistent mRNA expression of proinflammatory cytokines and absent expression of inter-leukin-10 and transforming growth factor-beta. J Neuro-immunol 1996; 69: 103-115.
21. Olsson T, Zhi WW, Hojeberg B, Kostulas V, Jiang YP, Anderson G et al. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gam-ma. J Clin Invest 1990; 86: 981-985.
22. Olsson T. Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis. Neurology 1995; 45: S11-S15.
23. Olofsson P, Nordquist N, Vingsbo-Lundberg C, Larsson A, Falkenberg C, Pettersson U et al. Genetic links between the acute-phase response and arthritis development in rats. Arthritis Rheum 2002; 46: 259-268.
24. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324.
25. Vingsbo-Lundberg C, Nordquist N, Olofsson P, Sundvall M, Saxne T, Pettersson U et al. Genetic control of arthritis onset, severity and chronicity in a model for rheumatoid arthritis in rats. Nat Genet 1998; 20: 401-404.
26. Xu H, Wallstrom E, Becanovic K, Dahlman I, Lorentzen JC. Identification of rat quantitative trait loci that regulate LPS-induced pro-inflammatory cytokine responses. Scand J Immunol 2002; 56: 248-253.
27. Bergsteinsdottir K, Yang HT, Pettersson U, Holmdahl R. Evidence for common autoimmune disease genes controlling onset, severity, and chronicity based on experimental models for multiple sclerosis and rheumatoid arthritis. J Immunol 2000; 164: 1564-1568.
28. Lu S, Nordquist N, Holmberg J, Olofsson P, Pettersson U, Holmdahl R. Both common and unique susceptibility genes in different rat strains with pristane-induced arthritis. Eur J Hum Genet 2002; 10: 475-483.
29. Jagodic M, Becanovic K, Sheng JR, Wu X, Backdahl L, Lorentzen JC et al. An advanced intercross line resolves Eae18 into two narrow quantitative trait loci syntenic to multiple sclerosis candidate loci. J Immunol 2004; 173: 1366-1373.
30. Zou GY. On the estimation of additive interaction by use of the four-by-two table and beyond. Am J Epidemiol 2008; 168: 212-224.
31. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661-678.
32. Mirel DB, Barcellos LF, Wang J, Hauser SL, Oksenberg JR, Erlich HA. Analysis of IL4R haplotypes in predisposition to multiple sclerosis. Genes Immun 2004; 5: 138-141.
33. Suppiah V, Goris A, Alloza I, Heggarty S, Dubois B, Carton H et al. Polymorphisms in the interleukin-4 and IL-4 receptor genes and multiple sclerosis: a study in Spanish-Basque, Northern Irish and Belgian populations. Int J Immunogenet 2005; 32: 383-388.
34. Quirico-Santos T, Suppiah V, Heggarty S, Caetano R, Alves-Leon S, Vandenbroeck K. Study of polymorphisms in the interleukin-4 and IL-4 receptor genes in a population of Brazilian patients with multiple sclerosis. Arq Neuropsiquiatr 2007; 65: 15-19.
35. Monnier PP, Sierra A, Macchi P, Deitinghoff L, Andersen JS, Mann M et al. RGM is a repulsive guidance molecule for retinal axons. Nature 2002; 419: 392-395.
36. Matsunaga E, Chedotal A. Repulsive guidance molecule/neogenin: a novel ligand-receptor system playing multiple roles in neural development. Dev Growth Differ 2004; 46: 481-486.
37. Matsunaga E, Nakamura H, Chedotal A. Repulsive guidance molecule plays multiple roles in neuronal differentiation and axon guidance. J Neurosci 2006; 26: 6082-6088.
38. Yamashita T, Mueller BK, Hata K. Neogenin and repulsive guidance molecule signaling in the central nervous system. Curr Opin Neurobiol 2007; 17: 29-34.
39. De Vries M, Cooper HM. Emerging roles for neogenin and its ligands in CNS development. J Neurochem 2008; 106: 1483-1492.
40. Schwab JM, Monnier PP, Schluesener HJ, Conrad S, Beschor-ner R, Chen L et al. Central nervous system injury-induced repulsive guidance molecule expression in the adult human brain. Arch Neurol 2005; 62: 1561-1568.
41. Gracie JA, Bradley JA. Interleukin-12 induces interferon-gamma-dependent switching of IgG alloantibody subclass. Eur J Immunol 1996; 26: 1217-1221.
42. Hata K, Fujitani M, Yasuda Y, Doya H, Saito T, Yamagishi S et al. RGMa inhibition promotes axonal growth and recovery after spinal cord injury. J Cell Biol 2006; 173: 47-58.
43. Conrad S, Genth H, Hofmann F, Just I, Skutella T. Neogenin-RGMa signaling at the growth cone is bone morphogenetic protein-independent and involves RhoA, ROCK, and PKC. J Biol Chem 2007; 282: 16423-16433.
44. Kubo T, Endo M, Hata K, Taniguchi J, Kitajo K, Tomura S et al. Myosin IIA is required for neurite outgrowth inhibition produced by repulsive guidance molecule. J Neurochem 2008; 105: 113-126.
45. Paintlia AS, Paintlia MK, Singh AK, Singh I. Inhibition of rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis. Mol Pharmacol 2008; 73: 1381-1393.
46. Walters CE, Pryce G, Hankey DJ, Sebti SM, Hamilton AD, Baker D et al. Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis. J Immunol 2002; 168: 4087-4094.
47. Zhang Z, Schittenhelm J, Meyermann R, Schluesener HJ. Lesional accumulation of RhoA(+) cells in brains of experimental autoimmune encephalomyelitis and multiple sclerosis. Neuropathol Appl Neurobiol 2008; 34: 231-240.
48. Hackstein H, Bitsch A, Bohnert A, Hofmann H, Weber F, Ohly A et al. Analysis of interleukin-4 receptor alpha chain variants in multiple sclerosis. J Neuroimmunol 2001; 113: 240-248. (Pubitemid 32112751)
49. Webb R, Merrill JT, Kelly JA, Sestak A, Kaufman KM, Langefeld CD et al. A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum 2009; 60: 2402-2407.
50. Spolski R, Leonard WJ. Interleukin-21: Basic biology and implications for cancer and autoimmunity. Annual Review of Immunology 2008; 26: 57-79.
51. Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B et al. TRAF1-C5 as a risk locus for rheumatoid arthritis\a genomewide study. N Engl J Med 2007; 357: 1199-1209.
52. Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009; 18: 767-778.
53. Amor S, Groome N, Linington C, Morris MM, Dornmair K, Gardinier MV et al. Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice. J Immunol 1994; 153: 4349-4356.
54. Carlson BC, Jansson AM, Larsson A, Bucht A, Lorentzen JC. The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats. Am J Pathol 2000; 156: 2057-2065.
55. Broman KW, Wu H, Sen S, Churchill GA. R/qtl: QTL mapping in experimental crosses. Bioinformatics 2003; 19: 889-890.
56. Lander ES, Botstein D. Mapping mendelian factors underlying quantitative traits using RFLP linkage maps. Genetics 1989; 121: 185-199.
57. Manichaikul A, Dupuis J, Sen S, Broman KW. Poor performance of bootstrap confidence intervals for the location of a quantitative trait locus. Genetics 2006; 174: 481-489.
58. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
59. Roos IM, Kockum I, Hillert J. The interleukin 23 receptor gene in multiple sclerosis: a case-control study. J Neuroimmunol 2008; 194: 173-180.
60. Isler JA, Vesterqvist OE, Burczynski ME. Analytical validation of genotyping assays in the biomarker laboratory. Pharmaco-genomics 2007; 8: 353-368.
61. Ekelund E, Saaf A, Tengvall-Linder M, Melen E, Link J, Barker J et al. Elevated expression and genetic association links the SOCS3 gene to atopic dermatitis. Am J Hum Genet 2006; 78: 1060-1065.
62. Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered 2008; 66: 87-98.
63. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96: 434-442.